Johnson & Johnson Accepts Offer from The Carlyle Group to Acquire Ortho‑Clinical Diagnostics for $4 Billion
April 02, 2014
On March 31, 2014, Johnson & Johnson announced that it has accepted the binding offer from The Carlyle Group, which was received and announced on January 16, 2014, to acquire its Ortho‑Clinical Diagnostics business for approximately US$4 billion, subject to customary adjustments. Cravath represented Johnson & Johnson in connection with this transaction. The transaction is expected to close toward the middle of the year, upon satisfaction of customary closing conditions.
The Cravath team included partner Robert I. Townsend III and associates Alexander Muller and Stephanie L. Alexis on M&A matters and associate Jarrett R. Hoffman on executive compensation and benefits matters. Ryan M. Farha and Mathieu Francon also worked on M&A matters and Matthew J. Bobby also worked on executive compensation and benefits matters.
Related Practices & Industries
People
- Photo
-
-
J.D., 1990, Harvard Law Schoolmagna cum laude
-
A.B., 1987, Harvard Collegemagna cum laude
- New York
Education
Admitted In
Related News & Insights
Deals & Cases
November 17, 2025
Johnson & Johnson’s $3.05 Billion Acquisition of Halda Therapeutics OpCo, Inc.
On November 17, 2025, Johnson & Johnson announced it has entered into a definitive agreement to acquire Halda Therapeutics OpCo, Inc., a clinical‑stage biotechnology company with a proprietary Regulated Induced Proximity TArgeting Chimera (RIPTACTM) platform to develop oral, targeted therapies for multiple types of solid tumors, including prostate cancer, for $3.05 billion in cash. Cravath is representing Johnson & Johnson in connection with the transaction.
Deals & Cases
March 12, 2025
Johnson & Johnson’s $5 Billion Registered Notes Offering and Concurrent €4 Billion Notes Offering
Cravath represented the underwriters in connection with the $5 billion registered notes offering of Johnson & Johnson, the world’s largest, most diversified healthcare products company. Cravath also represented the underwriters in connection with Johnson & Johnson’s concurrent €4 billion notes offering. Proceeds of both offerings will be used to finance the acquisition of Intra‑Cellular Therapies, Inc. by Johnson & Johnson. The transactions closed on February 20, 2025, and February 26, 2025, respectively.
